Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid

Background: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of...

Full description

Bibliographic Details
Main Authors: Erika Oliveira Hansen, Natalia Silva Dias, Ivonne Carolina Bolaños Burgos, Monica Vieira Costa, Andréa Teixeira Carvalho, Antonio Lucio Teixeira, Izabela Guimarães Barbosa, Lorena Aline Valu Santos, Daniela Valadão Freitas Rosa, Aloisio Joaquim Freitas Ribeiro, Bernardo Mattos Viana, Maria Aparecida Camargos Bicalho
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Psychiatry
Subjects:
tau
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/full
id doaj-d24628b7ebb84afe9364f2ce9f2d915e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Erika Oliveira Hansen
Erika Oliveira Hansen
Natalia Silva Dias
Natalia Silva Dias
Ivonne Carolina Bolaños Burgos
Monica Vieira Costa
Andréa Teixeira Carvalho
Antonio Lucio Teixeira
Antonio Lucio Teixeira
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Lorena Aline Valu Santos
Daniela Valadão Freitas Rosa
Aloisio Joaquim Freitas Ribeiro
Bernardo Mattos Viana
Bernardo Mattos Viana
Bernardo Mattos Viana
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
spellingShingle Erika Oliveira Hansen
Erika Oliveira Hansen
Natalia Silva Dias
Natalia Silva Dias
Ivonne Carolina Bolaños Burgos
Monica Vieira Costa
Andréa Teixeira Carvalho
Antonio Lucio Teixeira
Antonio Lucio Teixeira
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Lorena Aline Valu Santos
Daniela Valadão Freitas Rosa
Aloisio Joaquim Freitas Ribeiro
Bernardo Mattos Viana
Bernardo Mattos Viana
Bernardo Mattos Viana
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
Frontiers in Psychiatry
Alzheimer's disease
biomarker
Millipore xMap® Luminex
cerebrospinal fluid
Aβ42
tau
author_facet Erika Oliveira Hansen
Erika Oliveira Hansen
Natalia Silva Dias
Natalia Silva Dias
Ivonne Carolina Bolaños Burgos
Monica Vieira Costa
Andréa Teixeira Carvalho
Antonio Lucio Teixeira
Antonio Lucio Teixeira
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Izabela Guimarães Barbosa
Lorena Aline Valu Santos
Daniela Valadão Freitas Rosa
Aloisio Joaquim Freitas Ribeiro
Bernardo Mattos Viana
Bernardo Mattos Viana
Bernardo Mattos Viana
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
Maria Aparecida Camargos Bicalho
author_sort Erika Oliveira Hansen
title Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
title_short Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
title_full Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
title_fullStr Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
title_full_unstemmed Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid
title_sort millipore xmap® luminex (hatmag-68k): an accurate and cost-effective method for evaluating alzheimer's biomarkers in cerebrospinal fluid
publisher Frontiers Media S.A.
series Frontiers in Psychiatry
issn 1664-0640
publishDate 2021-08-01
description Background: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of the most well-known methods limits their use in low and medium-income countries. In this context, Millipore xMap® Luminex may be a cost-effective alternative. In our study, using INNOTEST® as reference, we assess the diagnostic accuracy of Millipore xMap® and propose a cutoff point for AD.Methods: We performed lumbar puncture of seven older individuals with clinically defined AD, 17 with amnestic mild cognitive impairment (aMCI) and 11 without objective cognitive impairment-control group (CG). Cerebrospinal fluid (CSF) biomarkers concentrations for aB42, p-Tau, and t-Tau were measured by INNOTEST® and Millipore xMap®, and then the techniques were compared to assess the diagnostic accuracy of the new test and to define a cutoff.Results: INNOTEST® and Millipore xMap® measurements showed all correlations >0.8 for the same biomarker, except for t-Tau that was 0.66. Millipore xMap® measurements showed a robust accuracy for all biomarkers, with AUC higher than 0.808 (t-Tau), and the best for Aβ42 (AUC = 0.952). The most accurate cutoffs were found at 1012.98 pg/ml (Aβ42), 64.54 pg/ml (p-tau), 3251.81 pg/ml (t-tau), 3.370 (t-Tau/Aβ42), and 0.059 (p-Tau/Aβ42).Conclusion: Given its good accuracy and cost-effectiveness, Milliplex xMap® tests seems a reliable and promising tool, especially for low and middle-income countries.
topic Alzheimer's disease
biomarker
Millipore xMap® Luminex
cerebrospinal fluid
Aβ42
tau
url https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/full
work_keys_str_mv AT erikaoliveirahansen milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT erikaoliveirahansen milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT nataliasilvadias milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT nataliasilvadias milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT ivonnecarolinabolanosburgos milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT monicavieiracosta milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT andreateixeiracarvalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT antoniolucioteixeira milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT antoniolucioteixeira milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT izabelaguimaraesbarbosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT lorenaalinevalusantos milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT danielavaladaofreitasrosa milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT aloisiojoaquimfreitasribeiro milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT bernardomattosviana milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
AT mariaaparecidacamargosbicalho milliporexmapluminexhatmag68kanaccurateandcosteffectivemethodforevaluatingalzheimersbiomarkersincerebrospinalfluid
_version_ 1717815849416392704
spelling doaj-d24628b7ebb84afe9364f2ce9f2d915e2021-09-03T20:12:02ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402021-08-011210.3389/fpsyt.2021.716686716686Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal FluidErika Oliveira Hansen0Erika Oliveira Hansen1Natalia Silva Dias2Natalia Silva Dias3Ivonne Carolina Bolaños Burgos4Monica Vieira Costa5Andréa Teixeira Carvalho6Antonio Lucio Teixeira7Antonio Lucio Teixeira8Izabela Guimarães Barbosa9Izabela Guimarães Barbosa10Izabela Guimarães Barbosa11Lorena Aline Valu Santos12Daniela Valadão Freitas Rosa13Aloisio Joaquim Freitas Ribeiro14Bernardo Mattos Viana15Bernardo Mattos Viana16Bernardo Mattos Viana17Maria Aparecida Camargos Bicalho18Maria Aparecida Camargos Bicalho19Maria Aparecida Camargos Bicalho20Maria Aparecida Camargos Bicalho21Maria Aparecida Camargos Bicalho22Jenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilNeuroscience Program, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilAdult Health Sciences Applied Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilRené Rachou Institute, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, BrazilDepartment of Psychiatry and Behavioral Sciences, UT Health, Houston, TX, United StatesInstituto de Ensino e Pesquisa, Santa Casa de Belo Horizonte, Belo Horizonte, BrazilNeuroscience Program, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilDepartment of Mental Health, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil1Institute of Exact Sciences, Statistics Department, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilJenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilDepartment of Mental Health, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilJenny de Andrade Faria Institute– Reference Center for the Elderly, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilMolecular Medicine Program, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilElderly Psychiatry and Psychology Extension Program (PROEPSI), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil0National Institute of Science and Technology of Molecular Medicine (INCT-MM), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil2Department of Clinical Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilBackground: Alzheimer's disease (AD) biomarkers are of great relevance in clinical research, especially after the AT(N) framework. They enable early diagnosis, disease staging and research with new promising drugs, monitoring therapeutic response. However, the high cost and low availability of the most well-known methods limits their use in low and medium-income countries. In this context, Millipore xMap® Luminex may be a cost-effective alternative. In our study, using INNOTEST® as reference, we assess the diagnostic accuracy of Millipore xMap® and propose a cutoff point for AD.Methods: We performed lumbar puncture of seven older individuals with clinically defined AD, 17 with amnestic mild cognitive impairment (aMCI) and 11 without objective cognitive impairment-control group (CG). Cerebrospinal fluid (CSF) biomarkers concentrations for aB42, p-Tau, and t-Tau were measured by INNOTEST® and Millipore xMap®, and then the techniques were compared to assess the diagnostic accuracy of the new test and to define a cutoff.Results: INNOTEST® and Millipore xMap® measurements showed all correlations >0.8 for the same biomarker, except for t-Tau that was 0.66. Millipore xMap® measurements showed a robust accuracy for all biomarkers, with AUC higher than 0.808 (t-Tau), and the best for Aβ42 (AUC = 0.952). The most accurate cutoffs were found at 1012.98 pg/ml (Aβ42), 64.54 pg/ml (p-tau), 3251.81 pg/ml (t-tau), 3.370 (t-Tau/Aβ42), and 0.059 (p-Tau/Aβ42).Conclusion: Given its good accuracy and cost-effectiveness, Milliplex xMap® tests seems a reliable and promising tool, especially for low and middle-income countries.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.716686/fullAlzheimer's diseasebiomarkerMillipore xMap® Luminexcerebrospinal fluidAβ42tau